Current Edition


GamaMabs Pharma sees two peer-reviewed articles published in Oncotarget, detailing the anti-tumor activity of GM102/3C23K

GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting AMHR2 for the treatment of cancer, today announces that two peer-reviewed articles have been published …

Continue Reading →
clinical trial

Bevacizumab leads clinical trial activity for monoclonal antibodies, says GlobalData

When tracking clinical trial activity across the world, GlobalData, a leading data and analytics company, identified 5,273 industry monoclonal antibodies (mAb) clinical trials with a …

Continue Reading →